Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial stragegy

dc.contributor.author
Moles Meler, Ernest
dc.contributor.author
Urbán, Patricia
dc.contributor.author
Jiménez-Díaz, Maria Belén
dc.contributor.author
Viera-Morilla, Sara
dc.contributor.author
Angulo-Barturen, Iñigo
dc.contributor.author
Busquets i Viñas, Ma. Antonia
dc.contributor.author
Fernàndez Busquets, Xavier
dc.date.issued
2016-06-17T14:44:43Z
dc.date.issued
2016-06-17T14:44:43Z
dc.date.issued
2015-06-02
dc.date.issued
2016-06-17T14:44:48Z
dc.identifier
0168-3659
dc.identifier
https://hdl.handle.net/2445/99607
dc.identifier
653861
dc.identifier
26008752
dc.description.abstract
One of the most important factors behind resistance evolution in malaria is the failure to deliver sufficiently high amounts of drugs to early stages of Plasmodium-infected red blood cells (pRBCs). Despite having been considered for decades as a promising approach, the delivery of antimalarials encapsulated in immunoliposomes targeted to pRBCs has not progressed towards clinical applications, whereas in vitro assays rarely reach drug efficacy improvements above 10-fold. Here we show that encapsulation efficiencies reaching N96% are achieved for the weak basic drugs chloroquine (CQ) and primaquine using the pH gradient loading method in liposomes containing neutral saturated phospholipids. Targeting antibodies are best conjugated through their primary amino groups, adjusting chemical crosslinker concentration to retain significant antigen recognition. Antigens from non-parasitized RBCs have also been considered as targets for the delivery to the cell of drugs not affecting the erythrocytic metabolism. Using this strategy, we have achieved unprecedented complete nanocarrier targeting to early intraerythrocytic stages of the malaria parasite for which there is a lack of specific extracellular molecular tags. Immunoliposomes studded with monoclonal antibodies raised against the erythrocyte surface protein glycophorin A were capable of targeting 100% RBCs and pRBCs at the low concentration of 0.5 μM total lipid in the culture, with N95% of added liposomes retained on cell surfaces. When exposed for only 15 min to Plasmodium falciparum in vitro cultures of early stages, free CQ had no significant effect on the viability of the parasite up to 200 nM, whereas immunoliposomal 50 nM CQ completely arrested its growth. In vivo assays in mice showed that immunoliposomes cleared the pathogen below detectable levels at a CQ dose of 0.5 mg/kg, whereas free CQ administered at 1.75 mg/kgwas, atmost, 40-fold less efficient. Our data suggest that this significant improvement is in part due to a prophylactic effect of CQ found by the pathogen in its host cell right at the very moment of invasion.
dc.format
13 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
Elsevier B.V.
dc.relation
Versió postprint del document publicat a: http://dx.doi.org/10.1016/j.jconrel.2015.05.284
dc.relation
Journal of Controlled Release, 2015, vol. 210, p. 217-229
dc.relation
http://dx.doi.org/10.1016/j.jconrel.2015.05.284
dc.rights
cc-by-nc-nd (c) Elsevier B.V., 2015
dc.rights
http://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject
Malària
dc.subject
Nanomedicina
dc.subject
Plasmodium falciparum
dc.subject
Sistemes d'alliberament de medicaments
dc.subject
Malaria
dc.subject
Nanomedicine
dc.subject
Plasmodium falciparum
dc.subject
Drug delivery systems
dc.title
Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial stragegy
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.